Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02402712
Title Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

Her2-receptor positive breast cancer

Therapies

Docetaxel + Pertuzumab + Trastuzumab

Age Groups: adult
Covered Countries ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.